Why Is ORUKA THERAPEUTICS I (ORKA) Stock Moving Today?

Oruka Therapeutics shares climbed 12.70% to $90.33 on Monday, driven by strong interim data from its Phase 2b trial. The company reported that 61% of patients receiving the highest dose of ORKA-001 achieved complete clearance of plaque psoriasis after 16 weeks, a result that significantly outperformed the placebo group.

What Happened

Oruka Therapeutics released week 16 results for ORKA-001 in the ongoing EVERLAST-B trial for plaque psoriasis. The data showed that 61% of patients on the 600 mg dose achieved PASI 100, compared to none in the placebo group. Additionally, 86% of patients in the treatment group achieved PASI 90 response rates. The company stated that ORKA-001 is on track to advance into Phase 3 trials in the first half of 2027.

Analyst reactions to the data were mixed but generally positive. Guggenheim reiterated its rating on the stock, noting that the psoriasis treatment could generate $7 billion in peak sales. Conversely, Clear Street lowered its price target to $105 from $131. Oruka Therapeutics filed a Form 8-K with the SEC on October 26, 2026, to disclose the Regulation FD information and related financial statements.

What The Data Shows

The stock printed 25 fresh 52-week highs on October 26, 2026, extending a strong recent trend. Over the last eight sessions, the shares have moved up 21.0%, rising from $74.65 to $90.33. The current price sits within the 52-week range of $25.23 to $115.52.

Insider activity has been predominantly selling over the past 90 days, with 16 sales totaling $22.0 million and no buys. Recent transactions include sales by Paul T. Quinlan, General Counsel, on October 20, 2026; Joana Goncalves, Chief Medical Officer, on October 15, 2026; and Arjun Agarwal, SVP of Finance, on October 12, 2026. The company has a market capitalization of $5.3 billion and remains unprofitable, with trailing twelve-month earnings per share of negative $2.02.

What To Watch

Investors will monitor the company's progress toward initiating Phase 3 trials in the first half of 2027. With coverage from eight sources in the last 36 hours, attention will remain on how the market digests the latest trial data and analyst price target adjustments.